Peringkat dalam Saham
#12747
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Harga Saham
$22.26
Terakhir disinkronkan: 2024-03-22
Kapitalisasi Pasar
$553.40M
Perubahan (1 tahun)
0.00%
Perdagangan Graphite Bio, Inc. (GRPH)
Harga GRPH dengan kapitalisasi pasar B
Kapitalisasi pasar dari Graphite Bio, Inc.(GRPH)
Kapitalisasi Pasar: $553.40M
Per August 2026, Graphite Bio, Inc. memiliki kapitalisasi pasar sebesar $553.40M. Ini menjadikan Graphite Bio, Inc. sebagai perusahaan 12747th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Graphite Bio, Inc. dari 2021 hingga 2026
GRPH dibandingkan dengan 5 teratas stocks paling populer
| Harga GRPH |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.264T
|
+951,087.60%
|
|
|
|
|
$4.701T
|
+849,426.54%
|
|
|
|
|
$4.177T
|
+754,721.34%
|
|
|
|
|
$3.817T
|
+689,709.24%
|
|
|
|
|
$2.866T
|
+517,850.72%
|
